# Apotransferrin in Patients With β-thalassemia

> **NCT03993613** · PHASE2 · TERMINATED · sponsor: **Prothya Biosolutions** · enrollment: 10 (actual)

## Conditions studied

- β-thalassemia Intermedia

## Interventions

- **BIOLOGICAL:** human apotransferrin

## Key facts

- **NCT ID:** NCT03993613
- **Lead sponsor:** Prothya Biosolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-21
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** no availability of IMP for this study
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993613, "Apotransferrin in Patients With β-thalassemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03993613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*